Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Gastrointestinal cancer

Over the RAINBOW—renaissance in antiangiogenesis

Nature Reviews Clinical Oncology volume 12, pages 7–8 (2015)Cite this article

Subjects

The RAINBOW study has demonstrated that ramucirumab plus paclitaxel as second-line treatment for advanced-stage gastric cancer prolongs survival compared with paclitaxel alone. These data confirm that ramucirumab represents a new effective treatment option for gastric cancer. Nevertheless, new treatment options remain eagerly awaited in this disease with dismal outcomes.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Algorithm for allocating second-line treatment of advanced-stage gastric cancer.

References

  1. Suzuki, S. et al. Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphorylation, and microvessel density in gastric cancer. BMC Cancer 10, 659 (2010).

    Article  CAS  Google Scholar 

  2. Ohtsu, A. et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J. Clin. Oncol. 29, 3968–3976 (2011).

    Article  CAS  Google Scholar 

  3. Lordick, F. Gastrointestinal cancer: Salvage chemotherapy in gastric cancer—more than a straw? Nat. Rev. Clin. Oncol. 9, 312–313 (2012).

    Article  CAS  Google Scholar 

  4. Wilke, H. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 15, 1224–1235 (2014).

    Article  CAS  Google Scholar 

  5. Fuchs, C. S. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383, 31–39 (2014).

    Article  CAS  Google Scholar 

  6. Li, J. et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J. Clin. Oncol. 31, 3219–3225 (2013).

    Article  CAS  Google Scholar 

  7. Okines, A. F. et al. Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report. Ann. Oncol. 24, 702–709 (2013).

    Article  CAS  Google Scholar 

  8. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202–209 (2014).

  9. Yoon, H. H. et al. Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicentre phase 2 trial [abstract]. J. Clin. Oncol. 32 (Suppl.), a4004 (2014).

    Article  Google Scholar 

  10. Lordick, F. et al. Unmet needs and challenges in gastric cancer: the way forward. Cancer Treat. Rev. 40, 692–700 (2014).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Cancer Centre Leipzig (UCCL), University Hospital Leipzig, Liebigstrasse 20, Leipzig, D–04103, Germany

    Florian Lordick

Authors
  1. Florian Lordick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Florian Lordick.

Ethics declarations

Competing interests

F.L. and his institution have received grants for research support from Fresenius Biotech, GSK and Merck-Serono. F.L. received travel support from Amgen, Merck-Serono and Roche. The University Hospital Leipzig receives lecture and advisory honoraria from Amgen, Celgene, Lilly, Merck-Serono, Roche, and Taiho.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lordick, F. Over the RAINBOW—renaissance in antiangiogenesis. Nat Rev Clin Oncol 12, 7–8 (2015). https://doi.org/10.1038/nrclinonc.2014.195

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2014.195

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer